CRISPR Therapeutics AG $CRSP Shares Purchased by Profund Advisors LLC

Posted by Geri Gentry on Nov 2nd, 2026

Profund Advisors LLC increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 42.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,562 shares of the company’s stock after purchasing an additional 12,479 shares during the quarter. Profund Advisors LLC’s holdings in CRISPR Therapeutics were worth $2,299,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CRSP. Swiss National Bank grew its holdings in shares of CRISPR Therapeutics by 5.1% during the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock worth $8,073,000 after buying an additional 8,200 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of CRISPR Therapeutics in the first quarter worth about $7,136,000. KBC Group NV boosted its position in CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Congress Asset Management Co. grew its stake in CRISPR Therapeutics by 1.6% during the 3rd quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock valued at $6,153,000 after acquiring an additional 1,777 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in CRISPR Therapeutics by 29.6% during the 1st quarter. California State Teachers Retirement System now owns 101,232 shares of the company’s stock valued at $4,816,000 after acquiring an additional 23,109 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $51.42 on Monday. The firm’s fifty day moving average price is $54.19 and its 200 day moving average price is $52.92. CRISPR Therapeutics AG has a 12 month low of $44.12 and a 12 month high of $65.98. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The company has a market capitalization of $4.97 billion, a price-to-earnings ratio of -10.80 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $10.18 million during the quarter. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -4.44 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $57.09, for a total transaction of $780,934.11. Following the sale, the director owned 16,637 shares in the company, valued at approximately $949,806.33. The trade was a 45.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the sale, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. This trade represents a 13.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on CRSP shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Citizens Jmp reiterated a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a report on Monday, August 31st. Finally, Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Moderate Buy” and an average price target of $65.75.

Get Our Latest Stock Analysis on CRSP

CRISPR Therapeutics Profile

(Free Report)

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.